MedPath

Phase 3 study of cetirizine dry syrup in children suffering from atopic dermatitis.

Phase 3
Conditions
Atopic dermatitis
Registration Number
JPRN-jRCT2080220120
Lead Sponsor
GlaxoSmithKline K.K.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
Not specified
Target Recruitment
278
Inclusion Criteria

Age: 3 to 14, Children with atopic dermatitis, patients eligible for evaluation of pruitus, etc.

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in the severity of pruritus, safety etc.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath